Cholecystokinin, dopamine D2 and N-methyl-D-aspartate binding sites in the nucleus of the solitary tract of the rat: possible relationship to ingestive behavior.
Receptor autoradiography was used to investigate the distribution of brainstem binding sites for cholecystokinin, dopamine and N-methyl-D-aspartate with particular reference to the nucleus of the solitary tract of the rat, an area involved in the control of ingestive behavior. Binding sites for the A and B subtypes of the cholecystokinin receptor, labeled with [(125)I]cholecystokinin octapeptide sulfate in the presence or absence of antagonists for the devazepide (A) or L-365,260 (B) receptor, were present throughout the caudal rostral extent of the nucleus of the solitary tract, the A type predominating in the commissural, medial and gelatinous part and the B type in the lateral part. In the most rostral part of the medial nucleus of the solitary tract, both A and B receptors were present. Dopamine D2 receptors, labeled with [(125)I]NCQ-298, were found in all parts of the nucleus of the solitary tract. No binding to the dopamine D1 receptor, labeled with [(125)I]SCH-23982, was found in the brainstem. N-Methyl-D-aspartate receptors, labeled with [(3)H]dizocilpine maleate, were also present in the entire caudorostral extent of the nucleus of the solitary tract. Binding to cholecystokinin A receptors was co-distributed with [(125)I]NCQ-298 and [(3)H]dizocilpine maleate binding in the caudal and rostral parts of the nucleus of the solitary tract, and binding to cholecystokinin B receptors overlapped with [(125)I]NCQ-298 and [(3)H]dizocilpine maleate binding in the rostral nucleus of the solitary tract. These results are consistent with the hypothesis that cholecystokinin, dopamine and glutamate interact in the nucleus of the solitary tract in the control of ingestive behavior.
Qian
M
M
Department of Clinical Neuroscience, Karolinska Institute, Novum, Huddinge, Sweden.
Johnson
A E
AE
Källström
L
L
Carrer
H
H
Södersten
P
P
D000818:Animals; D001345:Autoradiography; D001522:Behavior, Animal / Q000502:physiology; D001552:Benzazepines / Q000031:analogs & derivatives / Q000494:pharmacology; D016291:Dizocilpine Maleate / Q000494:pharmacology; D018491:Dopamine Agonists / Q000494:pharmacology; D018492:Dopamine Antagonists / Q000494:pharmacology; D065127:Dopamine D2 Receptor Antagonists; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D005247:Feeding Behavior / Q000502:physiology*; D007457:Iodine Radioisotopes; D008297:Male; D018697:Nootropic Agents / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D011949:Receptors, Cholecystokinin / Q000819:agonists / Q000032:analysis*; D017448:Receptors, Dopamine D2 / Q000819:agonists / Q000032:analysis*; D016194:Receptors, N-Methyl-D-Aspartate / Q000032:analysis* / Q000037:antagonists & inhibitors; D012457:Salicylamides / Q000494:pharmacology; D012844:Sincalide / Q000031:analogs & derivatives / Q000494:pharmacology; D017552:Solitary Nucleus / Q000737:chemistry / Q000502:physiology*; D014316:Tritium
C049558:8-iodo-2,3,4,5-tetrahydro-3-methyl-5-phenyl-1H-3-benzazepine-7-ol; C090019:8-sulfocholecystokinin octapeptide; D001552:Benzazepines; D018491:Dopamine Agonists; D018492:Dopamine Antagonists; D065127:Dopamine D2 Receptor Antagonists; D018691:Excitatory Amino Acid Antagonists; D007457:Iodine Radioisotopes; D018697:Nootropic Agents; D011949:Receptors, Cholecystokinin; D017448:Receptors, Dopamine D2; D016194:Receptors, N-Methyl-D-Aspartate; D012457:Salicylamides; D014316:Tritium; D016291:Dizocilpine Maleate; D012844:Sincalide; C064246:NCQ 298